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The ‘PREXCEL-Q Method’ for qPCR
Abstract
The purpose of this manuscript is to describe a reliable approach to quantitative real-time polymerase chain
reaction (qPCR) assay development and project management, which is currently embodied in the Excel
2003-based software program named “PREXCEL-Q” (P-Q) (formerly known as “FocusField2-6Gallup-
qPCRSet-upTool-001,” “FF2-6-001 qPCR set-up tool” or “Iowa State University Research Foundation
[ISURF] project #03407”). Since its inception from 1997-2007, the program has been well-received and
requested around the world and was recently unveiled by its inventor at the 2008 Cambridge Healthtech
Institute’s Fourth Annual qPCR Conference in San Diego, CA. P-Q was subsequently mentioned in a review
article by Stephen A. Bustin, an acknowledged leader in the qPCR field. Due to its success and growing
popularity, and the fact that P-Q introduces a unique/defined approach to qPCR, a concise description of
what the program is and what it does has become important. Sample-related inhibitory problems of the qPCR
assay, sample concentration limitations, nuclease-treatment, reverse transcription (RT) and master mix
formulations are all addressed by the program, enabling investigators to quickly, consistently and confidently
design uninhibited, dynamically-sound, LOG-linear-amplification-capable, high-efficiency-of-amplification
reactions for any type of qPCR. The current version of the program can handle an infinite number of samples.
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PrEFAcE
As real-time fluorogenic quantitative polymerase chain 
reaction (qPCR) is now accepted as the most powerful tool 
in all of molecular biology for quantitative analysis of gene 
expression, and since it is the tool of choice for validating 
gene micro-array and other data, any new implement that 
improves its execution represents an important construc-
tive advance in furthering the responsible evolution of an 
important scientific technique (1). Despite its widespread 
use and essential role in most medical, biological, and life-
science laboratories, qPCR is challenging from a technical 
standpoint due to: 1) the numerous calculations required, 
and 2) the inhibition of key enzymatic reactions by a myriad 
of substances which can severely impact the precision of 
absolute and relative quantitative gene expression analysis. 
PREXCEL-Q (P-Q) addresses these concerns head-on and 
automates and speeds up qPCR calculations (from hours to 
seconds) with precision, thereby eliminating human error 
and reducing reagent waste to a minimum. It also identi-
fies and avoids inhibition of reverse transcription (RT) and 
qPCR reactions, identifies the valid LOG-linear-amplifica-
tion-capable ranges for all target standard curves, calculates 
the valid dilution series for each nucleic acid sample on a 
per target basis, and is able to achieve nearly 100% reac-
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tion efficiency for most final qPCR target reactions (assum-
ing appropriate primer-probe designs are already in place). 
There is no other similar comprehensive program. The cur-
rent Excel 2003-based version of P-Q is increasingly being 
used by laboratories at Iowa State University, other Ameri-
can universities, in the United Kingdom and in other places 
across Europe. Our current efforts are focused on building 
a graphical user interface (GUI) for the program by con-
verting the Excel 2003-based P-Q version entirely to Java 
for universal computer access, evaluating the developing 
GUI via target user feedback, documenting the GUI code, 
and creating a highly intuitive user manual and interactive 
Iowa State University-based P-Q website. A P-Q output file 
for liquid handling robots will also be developed. Our long-
term goal is to make P-Q easy to use and easily accessible to 
all laboratories performing qPCR across the world (2).
INtrODUctION
The principles which underlie the successful execution 
of qPCR invariably center on initial sample preparation. 
But, in addition to this, and of no lesser importance, con-
sistency of technique, from the very beginning to the very 
end of each assay is required so that all experimental sam-
ples are given the best possible, most scientifically-plau-
sible chance to truthfully reveal the secrets they conceal.
Common difficulties that have persisted over the years 
with qPCR include: a) the time involved in correctly per-
forming nuclease treatments, reverse transcription reac-
tions, kinetically-correct sample dilutions and master mix 
assemblies for the assays, and b) inhibition of the [RT and/
or Taq] reactions by a myriad of substances. These prob-
lems have caused many laboratories to take short cuts or 
to perform assays with a false sense of confidence (i.e. not 
knowing if or when RT and/or Taq polymerase inhibition 
is present). There is often also a tendency to pull back on 
assay complexity because of the tentative experiences in-
vestigators first have with qPCR. P-Q is an operational 
software program that can perform all concerned qPCR-
related calculations in seconds or minutes. In our hands, it 
has removed the danger of performing meaningless assays 
for days, weeks or months. In addition, it assists the user 
in attaining optimal sample, target and standard dilutions 
which avoid sample-related reaction inhibition and allows 
qPCR reactions to consistently attain high amplification 
reaction efficiencies. P-Q also establishes/suggests the 
[standard practice] use of a “Stock I” solution for all qPCR 
studies - which will serve to ensure the uniformity of all 
qPCR approaches and assessments, and therefore greatly 
improve the ability of different labs to consistently cross-
corroborate important gene expression results from mi-
cro-array and additional qPCR studies. Further, the use of 
“Stock I” to identify and avoid working within the inhibi-
tory range of the assay provides a means by which investi-
gators can arrive at the same results as those generated by 
correlate Northern Blot analyses, albeit with much greater 
sensitivity per unit sample amount.
background
basics of qPcr. Real-time polymerase chain reac-
tion, also termed “quantitative real-time PCR” (qPCR) is 
a technique used to amplify and quantify a specific por-
tion of a DNA (or cDNA) molecule. The DNA of cells is 
composed of sequences that code for specific proteins. For 
this to occur, DNA is transcribed to form messenger RNA 
(mRNA) which, after appropriate nucleolar- and spliceo-
some-related processing, is transported to the cytoplasm 
where it is translated into functional protein at the ribo-
some. The number of copies of mRNA transcribed from 
DNA roughly correlates with the amount of functional 
protein formed. Therefore, being able to quantify the 
number of copies of mRNA (mRNA level) provides in-
formation on: 1) the extent of transcription of a specific 
portion of DNA, and 2) the potential amount of functional 
protein. Traditionally, mRNA levels were determined by 
Northern Blot analysis; however, this technique requires 
relatively large amounts of RNA and cannot be performed 
on limited, small or partially degraded RNA samples. By 
contrast, with qPCR, a small specific stretch of RNA is 
converted to complementary DNA (cDNA) by an enzyme 
called reverse transcriptase (RT), and specific regions on 
target cDNAs can then be amplified by Thermus aquati-
cus (Taq) DNA-dependent DNA polymerase by a process 
known as the polymerase chain reaction (PCR) (22, 23). 
Using fluorophores, each round of DNA amplification can 
be detected and measured as it occurs, in “real time.” With 
TaqMan hydrolysis probe-based qPCR, amplification of 
specific regions on the cDNA is guided by primers (which 
are smaller stretches of synthesized DNA that bind known 
specific stretches of the target DNA or cDNA sequence; 
each with a Tm of ~60°C, typically). Between these sites, 
a synthesized fluorescent-capable (TaqMan™ hydrolysis) 
probe, specific to a portion of the intervening target se-
quence, also hybridizes (such probes are designed with Tm 
values typically ~10°C higher than the primers so that they 
bind to target sequence first, before the primer(s) do, ensur-
ing that all specific amplification events will be reported). 
The target DNA is amplified between (and including) the 
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primers by Taq polymerase which (by its unique 5’-3’ exo-
nuclease activity) sequentially degrades (hydrolyzes) the 
probe from the 5’ end, displacing the nucleotide containing 
the fluor from the formerly intact probe. Once this fluores-
cent portion of the probe is released and is no longer proxi-
mal to the quenching molecule (or quenching processes 
which are not dependent on exonuclease cleavage (10); see 
also the excellent animations by Biosearch Technologies 
at http://biosearchtech.com/download/flash_guides/for-
mats_explained.html) designed into the intact probe, it 
fluoresces, and the photomultiplier tube of any commer-
cial qPCR machine can detect its characteristic fluorescent 
signal wavelength. Geometric increase of the fluorescent 
signal corresponds to exponential increase in amplified se-
quences that, on a logarithmic scale, is linear and directly 
proportional to the initial amount of target sequence. 
The cycle at which the signal rises above “back-
ground” threshold is termed Ct (for “threshold cycle”) or 
CP (for “crossing point”). Most qPCR machines require 
about 1010 (ten billion) copies before the accrued fluo-
rescent signal is able to cross the threshold of detection 
(~10 standard deviations above background). Thus, at 
an amplification efficiency of 100%, the earliest qPCR 
signal from 1 copy of target nucleic acid should theoreti-
cally cross threshold at approximately cycle 33.22. But, 
due to the random ability of primers, probes and Taq 
to find single copy targets and initiate PCR in the reac-
tion tube or well, an approximate Ct spread of 34.37 ± 
1.15 would be expected. Stochastically speaking, 1 copy 
should always be able to amplify (in the absence of in-
hibitory phenomena), provided that the tested sample 
indeed contains the single target copy in the first place. 
The cycle at which the amplification first starts for such 
a single copy sample, however, has been experimentally 
observed to vary 5.5 cycles or more (34); and such sporad-
ic Ct values are emblematic of what is called the “Monte 
Carlo effect” - but this is expected in terms of the Pois-
son probability distribution of such events; e.g. Lockey 
et al. observed that, for 30 samples thought to contain at 
least one copy of target transcript, 63.2% of the samples 
would be expected to actually contain one or more cop-
ies while 36.8% of them would be expected to contain no 
target at all (10, 34). In other words, the random nature 
of PCR amplification reactions in general is exacerbated 
the fewer target molecules there are in an experimental 
sample to begin with going into the reaction (10). But, in 
samples containing 10 or more starting copies of target, 
the ability of qPCR to generate reliable signals improves 
rapidly and reliably (given an absence of RT and qPCR 
inhibitory phenomena) (10, 34). Since the quantity of each 
specifically-amplified DNA (amplicon) sequence doubles 
every cycle (at 100% efficiency), and since the rate of am-
plicon accumulation is directly proportional to the initial 
starting amount of each specific target sequence in each 
sample, each target can be quantified and compared to a 
standard curve containing dilutions of known or relative 
amounts of target sequence, and the measured amount of 
signal from a gene of interest is finally divided by the 
signal measured from a reference gene or the geometric 
mean of several reference genes (which are assumed to 
exhibit steady-state gene expression within cells) in order 
to correct for “sample loading” from sample to sample 
(an assumption that has become less and less acceptable 
over time and which underscores the importance of re-
sponsibly choosing appropriate, valid reference genes 
for the specific sample set at hand). Further, becoming 
more aware of the math that underlies qPCR can be very 
helpful when interpreting Ct values generated from un-
knowns and/or serial dilutions of a sample or sample mix-
ture. For example:  a) dn = {[1/LOG2(EAMP)] - 1} tells the 
investigator how many Ct units per cycle each successive 
dilution in a progressive dilution series will be expected 
to be off from the ideal expected occurrence of Ct val-
ues (e.g. when efficiency of amplification (E) = 100%; or 
EAMP = 2); b) LOGEAMP(serial dilution factor) = expected 
Ct frequency between successive samples in that serial 
dilution progression; c) Ct
observed
 ± LOGEAMP(serial dilution 
factor) = the next expected Ct in that dilution series; d) 
2(ΔCtideal/ΔCtobserved) = EAMP; e.) Relative quantity for any tar-
get = 10[(Ct-b)/m], and so on. An intercept-independent ap-
proximate equation for calculating the initial number of 
copies of a target (Xo) from any Ct when m is known can 
be expressed as:  Xo = 10
((Ct/m) + LOG10(Nt)) or Xo = 10
((Ct/m) + 10), 
wherein Nt is the number of target amplicons generated at 
100% E (EAMP = 2) at the threshold of detection (Ct) from 
the perfect amplification of 1 initial copy.  This Ct value 
should theoretically occur at 33.219 (or 10*[LOG
10
(2)-1]) 
cycles: 1 copy*233.219 cycles = 1010 copies = Nt = Xn = XCt = 
number of target copies at Ct. Thus, 1010 theoretically re-
mains constant at any Ct for any target evaluated at the 
same fluorescence (∆Rn) threshold fixed at approximately 
10 standard deviations above assay background. Interest-
ingly, an additional, more universal equation emerges for 
calculating Xo in all cases where sample and standard ma-
terial are experimentally “identical” (in keeping with the 
Stock I concept that this work encourages). This equation 
relies only three values: 1) a target’s Ct value; 2) the EAMP 
value for that target (as estimated from a Stock I-derived 
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standard curve); 3) the threshold value (T) at which the Ct 
value was obtained (using a ΔRn scale ranging from 0 to 
1; T values on this scale typically fall between 0.01 and 
0.5 in practice). Briefly:  
(A) Xo = TΔR *10
11*EAMP
-Ct
This expression, named the Gallup-Overstreet equa-
tion, revealed itself in conjunction with a series of in-
tensive qPCR experiments performed by Anne-Marie C. 
Overstreet on eight ASF bacterial strains in mice. When 
qPCR amplification curves are assessed using y-axis (re-
action fluorescence) scales that yield T values > 1 (36), 
the above approximation can be re-stated: 
(B) Xo = (FCt /Fmax)*10
11*EAMP
-Ct
When the “1010 amplicons at a ΔRn or FCt/Fmax thres-
hold of 0.1” assumption does not apply, the following 
threshold-independent equations (which allow the calcu-
lation of a y-intercept in terms of copies for experimental 
sample-derived relative dilution standard curves from 
the y-intercept evaluation of a corresponding absolute 
target template standard curve) can be applied:
(C) Absolute template:  Xo = 10
(-ba/ma)*EAMPa
-Cta
(D) Sample template:  Xo = 10
(-bs/ms)*EAMPs
-Cts
Here, the term “bs” in equation (D), is the calculated
copy number-associated y-intercept of the experimental 
sample-generated plot of: LOG of target copy number vs. 
Ct (not to be confused with the y-intercept obtained di-
rectly from the plot of: experimental sample-generated 
LOG of relative sample dilutions vs. Ct). bs is mathemati-
cally obtained as follows:
(E) bs = ba*LOG(EAMPa)/LOG(EAMPs)
This transformation assigns an appropriate copy number 
estimate to the calculated y-intercept value for the copy 
number-transformed relative-dilution target standard 
curves. However, when absolute standards are not used, 
above approximations (A) or (B) can be applied - but only 
cautiously, as they assume a stable (1010) number of am-
plicons to be generated at a threshold of 0.1 (37, 38).
Currently, qPCR is commonly used in life science 
laboratories in work ranging from microbes to plants 
as well as in medicine including human and veterinary. 
It is also a workhorse assay for diagnostic and forensic 
samples. However, although qPCR is informative on 
many fronts, leaders in the qPCR field have responsibly 
warned investigators and researchers to temper their en-
thusiasm over qPCR results by remembering that “qPCR 
data constitute only a snapshot of information regard-
ing the quantity of a given transcript in a cell or tissue. 
Any assessment of the biological consequences of vari-
able mRNA levels must include additional information 
regarding regulatory RNAs [miRNA, shRNA, siRNA], 
protein levels and protein activity” (29). In addition, the 
possibility that there are splice variants of every mes-
sage investigated must always be taken into account (10, 
http://lane.stanford.edu/howto/index.html?id=_2063 and 
http://medblog.stanford.edu/lane-faq/archives/research_
publishing/index.html). 
Technically, there are several basic considerations 
for setting-up qPCR assays which have been discussed 
at length in the literature (3). These include: a) decisions 
by the operator regarding design and concentrations of 
primers/probes, choice of the appropriate master mix 
(some containing both reverse transcriptase and Taq 
DNA polymerase, and others, just Taq DNA polymerase) 
to carry out either One- or Two-step qPCR; b) RNA iso-
lation and cDNA synthesis; c) selection of appropriate/
stable endogenous reference gene(s) or exogenous con-
trol sequence(s); d) determination of reaction efficiencies 
and valid dynamic dilution ranges for each target stan-
dard curve; e) kinetically-appropriate sample dilutions; 
f) correctly handling and processing samples derived by 
laser-capture microdissection (LCM); g) appropriately 
designing Test Plates. P-Q addresses each of the above 
(with the exception of primer design), allowing investiga-
tors to step almost immediately into the lab to commence 
with qPCR since all set-up calculations can be optimally 
performed by the program in minutes − as opposed to 
hours, days, weeks, months, even years otherwise spent 
in vain (Figs. 1 and 2).
Key problems with qPcr: set-up calculations and 
inhibition
calculations. As indicated, there are assay-specific 
key calculations required to perform qPCR correctly, 
some of which (e.g. appropriate sample/target and stan-
dard dilutions) are often entirely ignored (2, 4, 5, 6, 7, 8, 
9). After completing the calculations, laboratory personnel 
then need to perform pipetting procedures that can intro-
duce additional, compounding errors when the pipetted 
amounts of each reagent and/or sample are not planned out 
(and printed out) clearly beforehand. These are some of the 
commonly-understood real-life concerns with qPCR. Not 
only has P-Q reduced our perfunctory calculation time 
from hours to seconds or minutes, its recipe-like output re-
ports greatly minimize the occurrence of user-introduced 
procedural set-up errors. Most importantly, P-Q identifies 
and addresses the often ignored problem of sample-related 
inhibition that is likely commonplace in every laboratory 
performing qPCR.
n
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Figure 2. The danger of not working outside
the sample-inhibitory range of qPCR assays.
This is a Stock I sample mixture that has been 
diluted in order to identify the LOG-linear-
amplification-capable range for 18S ribosomal 
RNA (18S rRNA). Note that dilutions of 
Stock I with high and low amounts of 18S rRNA 
transcript can be mistakenly interpreted (if 
they were unknowns) as containing the same 
amount of 18S rRNA target message since 
they both generate virtually identical Ct  
values depending on the degree of inhibition 
present or absent at different sample dilutions. 
Both low dilution A (high amount of target 
transcript) and high dilution B (low amount of 
target transcript) generate the same Ct value 
(~19). P-Q avoids this problem with every 
sample and every target for each sample.
Figure 1.  qPCR-inhibitory behavior (top graph) of a Stock 
I solution at different dilutions. The qPCR data shown was 
collected for 7 targets of interest in ovine lung tissue from 
a P-Q Test Plate analysis preceding final qPCR set-ups for a 
56-sample experiment. Ct results generated at LOG-linear-
amplification-capable sample dilutions exhibit a straight 
line (middle graph), while the inhibitory dilution range is 
curved like a hook at lower sample dilutions (top graph). The 
red dotted oval encircles this “hook” portion within which 
most of the dilutions are inhibitory for each of the qPCR  
amplifications of the transcripts of interest. Within these  
inhibitory sample dilution regions, investigators will obtain 
results (Ct values); however, they will be wildly misleading 
and incorrect. For example, a sample diluted within the inhibitory 
dilution range will generate a target Ct that can be directly  
mistaken for a non-inhibited sample that actually has a low 
amount of that target (see Figure. 2). To the left of the red circle, 
where samples are more dilute, Cts become LOG-linear. Note 
that targets can differ for each of their optimal LOG-linear-
amplification-capable dilution ranges (bottom graph). Therefore, it 
is not accurate to simply dilute all samples to 1:200, for example. 
With some target transcripts, we have found optimal dilution 
ranges from 1:250-1:5000 (e.g., SBD-1) to 1:4000-1:4,000,000 
(e.g., RIBO 18S) within the same Stock I. P-Q identifies these 
precise LOG-linear-amplification-capable dilution ranges for 
each different sample and target, and the entire process for 
calculating these parameters for 7 targets is rapid (15-30 min-
utes) with P-Q.
The PREXCEL-Q Solution
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Inhibition. A variety of problematic inhibitory phe-
nomena has been reported that plague qPCR assays (2, 
4, 5, 6, 7, 8, 9). Inhibition of the enzymatic reactions 
involved in generating real-time qPCR signals from 
specific cDNA templates using specific primers, fluoro-
genic probes, or combinations of primers and fluorogenic 
probes can severely influence the precision of absolute 
and relative gene expression quantitative analysis. Any 
factor, experimental, user introduced, environmental or 
otherwise, that has an impact on the activity of RT (re-
verse transcriptase) enzyme and/or Taq DNA polymerase 
used in any real-time qPCR reaction will invariably af-
fect the results generated. In worst-case scenarios, these 
deficiencies go unnoticed, remain unaddressed and end 
up published as experimental “results.” Recently, others 
have suggested that many as yet unidentified sample-
specific substances (or impurities) are often carried over 
as a result of different RNA isolation methods (preced-
ing real-time qPCR of any variety) which cause RT en-
zyme- or Taq DNA polymerase-based qPCR inhibition 
(9, 10). Exogenous contaminants such as glove powder 
and phenolic compounds from the extraction process and 
plastic-ware (pipette tips, tubes and plates) can also have 
an inhibitory effect. With regard to tissue-specific inhi-
bition of DNA amplification, tissue type was found to be 
the largest source of variance of inhibitory phenomena 
while primer sequences appeared to have the least affect. 
In other words, tissue type from which total RNA was 
extracted had the most significant effect on PCR kinet-
ics, thus on final threshold cycle (Ct) values (9, 11). This 
is thought to be caused by different kinds and amounts of 
cellular debris present in samples after RNA extraction 
(9, 10). Endogenous contaminants such as blood or fat 
are thought to play an important role in affecting both 
the PCR as well as the preceding reverse transcription 
reaction. Other inhibitory contaminants are thought to be 
hemoglobin, heme, porphyrin, heparin (from peritoneal 
mast cells), glycogen, polysaccharides and proteins, cell 
constituents, Ca2+, DNA or RNA concentration, and DNA 
(and possibly RNA) binding proteins (12-18). MicroRNA 
(miRNA) is not thought to be a contributing factor to 
qPCR inhibition since high thermocycling temperatures 
(94-95°C) most likely prevent the formation of stable 
RNA-binding (RISC) complexes which might otherwise 
associate with template RNA. Inhibition is especially a 
problem with ancient DNA retrieved from archeological 
samples or other partially-preserved organisms that have 
either degraded or amassed qPCR-inhibitory contami-
nants over thousands and tens of thousands of years (4).
test Plate assessment of a representative mixture of 
samples: the “stock I” solution
A common problem with qPCR is selecting a sample 
that is representative of all samples in a study (to control 
for sample source variation, method of sample isolation, 
DNase treatment, RT conditions and serial dilution ef-
fects, etc), and a source of material to use for qPCR target 
standard curves. When completing a study with tissues 
from several mice or other animal species or even cul-
tured cells, where does one obtain an appropriately repre-
sentative RNA or DNA sample to test all of the genomic 
or transcriptomic targets of interest in each qPCR study? 
Some investigators pick one representative sample (e.g. 
Roche Applied Sciences “E-Method” (33)) while others 
use transcribed or reverse-transcribed linearized plasmid 
constructs as the representative test sample and as the 
standard curve material. We, however, pool small amounts 
of all or some of each current group of experimental sam-
ples and use the resulting mixture as the overall repre-
sentative sample in each of our qPCR studies; we have 
named such mixtures of experimental samples, “Stock I.” 
Stock I serves both as the serially diluted sample for each 
qPCR study’s preliminary “Test Plate” (which allows for 
the most realistic assessment of the qPCR dynamics of 
each sample and target of interest - the results of which are 
subsequently used/interpreted by P-Q to precisely define 
the valid dynamic boundaries of each entire qPCR study, 
per sample, per target, per isolation-method) and as the 
standard curve material on all final qPCR plates for indi-
vidual sample/qPCR target assessments. This is an origi-
nal (yet obvious) idea which, we feel, offers an excellent 
approach to qPCR which will help it achieve a consistent 
level of precision from lab to lab. Since the idea and use 
of a “Stock I” solution (which we introduced in 2001 and 
first published in 2004) (19) directly combats the only val-
id criticism of the Ct method by Sigmoidal Curve Fitting 
(SCF)-method proponents (e.g. standards and samples of-
ten not being comprised of the same material), (20), we 
have offered a viable solution to a dilemma facing qPCR 
users world-wide (the vast majority of whom will likely 
use Ct-based qPCR analysis for years to come). P-Q can 
also be used without the ‘Stock I solution’ option. Others 
have also recently observed that the “SavrgECt” method 
(which P-Q essentially accomplishes by virtue of its use 
of “Stock I”) is actually much more precise than any SCF-
based method for qPCR quantification. P-Q therefore 
theoretically attains the same precision, accuracy and ro-
bustness as the “2-∆∆Ct Method” when target amplification 
efficiencies are ~100% (21, 35).
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the PrEXcEL-Q Program Description
The P-Q program provides a simple, universal and 
standardized approach to qPCR which was first de-
scribed by the authors in 2006 (2) (see also Appendices 
1 and 2). Out of respect for those who have invented this 
brave technique (Mullis, Higuchi; 22, 23), this program 
is offered as a responsible follow-up implement which 
endeavors to ensure the fidelity of qPCR execution 
across the world. The future of P-Q involves its con-
version to a Java-based graphical user interface (GUI)-
driven program. It currently resides and works best in 
Microsoft Excel version 2003. Windows Office 2007 
Excel and Macintosh platforms are not generally able to 
run the program, although Macintosh computers loaded 
with Windows Excel 2003 (e.g. using Parallels 3.0) can 
be used to run the program in a Macintosh environment. 
P-Q’s restriction to Windows Excel 2003 is a little dis-
concerting, but Excel 2003 is still largely available at 
most universities and government agencies using qPCR 
throughout the world. But, indeed because of this, the 
program’s conversion to a universally-accessible Java-
based GUI format remains top priority for us as com-
puters and their associated operating systems will most 
certainly continue to evolve. Empirically, P-Q is a col-
lection of 27 interlinked Excel files commandeered by 
interwoven visual basic (VBA) macros and extensively 
layered, interdependent algorithms. The user interacts 
with mainly 5 of the 27 program files. Additional help-
ful Excel files (for sample preparation, DNase treatments 
and quick master mix set-ups) are also provided with the 
program - files that can be used in cases where the pro-
gram in its entirety is not called for. P-Q is Ct based. It 
relies on the threshold cycle (Ct) values generated on a 
Test Plate for the remainder of its functionality. Its goal 
is to help generate trustworthy Ct values, and, once these 
values are generated reliably, investigators can then pro-
cess them with confidence.
test Plate
The initial goal of the program is to establish a Test 
Plate (or validation plate) set-up using a representative 
sample mixture (made of a small portion of some or all of 
the experimental samples in each qPCR assay) to assess 
up to 7 targets of interest (per each instance of the pro-
gram) over a carefully selected progressive dilution series 
of the chosen sample mixture. This sample mixture, we 
have arbitrarily named “Stock I.” If investigators choose 
not to use the “Stock I approach,” the P-Q program can be 
used that way as well.
required User Input
First, from the user, the P-Q program needs the input 
of 7 basic parameters either into the program’s “Question-
naire.xls” file, into the “UMES.xls” file, or into both files: 
1) Sample-preparative information entered into cells I134 
and F135 of the “UMES.xls” file and into “Questionnaire.
xls” file cell range C6:M37, 260nm readings of all RNA or 
DNA samples at a known dilution (the factor for which is 
entered into “UMES.xls” file cell P137 and into “Ques-
tionnaire.xls” file cell G30 - which receive a value of “1” 
for samples measured at no dilution/full-strength; e.g. as 
with many NanoDrop readings) entered into “UMES.xls” 
file cell range B120:B191 along with the singular selection 
of the appropriate template extinction coefficient in cell 
range R150:R153, and selecting (using an “x” in cell range 
D120:D191) which samples will contribute to “Stock I,” 
and how many μL each sample will contribute to the cre-
ation of Stock I (which is either entered manually or entered 
automatically as calculated by the program) into “UMES.
xls” file cell F2, in addition, enter sample size prepared 
for the Test Plate into cell “UMES.xls” cell K2; 2) Ex-
act knowledge (parameter entries) of the conditions used 
for DNase or RNase treatments (these should be ‘identi-
cal’ for each sample) entered into cell range F138:F139 and 
K136:K139 of the “UMES.xls” file and within cell range 
G42:H57 of the “Questionnaire.xls” file; 3) Exact knowl-
edge (parameter entries) of the RT (reverse transcription) 
reaction assembly (these should also be ‘identical’ for each 
sample) entered into cell range N120:N121 and P134:P135 
of the “UMES.xls” file and within cell range P53:H79 of 
the “Questionnaire.xls” file; 4) The stock concentration 
of the primers and/or probes (all diluted to the same con-
centration; generally between 2 and 10 μM for singleplex 
qPCR as entered into “UMES.xls” file cell M117 and be-
tween 40 and 100 μM for multiplex qPCR as entered into 
“UMES.xls” cell S157) and the final in-wella nanomolar 
(nM) concentrations the primers/probes are each to be used 
at entered into “UMES.xls” file cell range H126:J132, with 
species and target names entered into cells F126:G132 ad-
jacent to that same region; 5) Any pre-knowledge pertain-
ing to the relative abundance of any or all of your targets of 
interest (e.g. if one already knows that the targets of inter-
est are “loud/robust” (relatively high-copy) signals in your 
samples and in your qPCR assays, testing Stock I dilution 
ranges from full-strength out to 1:1,000,000 dilution (in-
well) or greater for the Test Plate is justified. If the targets 
are known and/or thought to be relatively rarer, one should 
test a less extensive Stock I dilution series (e.g. from full-
strength out to 1:100,000, 1:50,000 or 1:10,000 or less) to 
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get an accurate preliminary picture of each sample’s qPCR 
targets’ behavior over an appropriately informative dilu-
tion series. Generally, a serial progressive dilution series 
ranging from full-strength out to 1:100,000 works in most 
situations (except for LCM nucleic acid isolates); 6) Draw-
ings of all final plates, and a good preliminary manual es-
timate of how much of each sample and standard will be 
required, and how many technical replicates will be used 
for samples, standards, NTCs, NRC/NAC samples (values 
for which are entered into “UMES.xls” file cells F55, F58, 
J17, J19, J20, J24, O25, U25 and AA25, respectively) and, 
7) User’s choice of either One-Step, Two-Step or LCM-
qPCR and specific knowledge of the relative strengths of 
the existing components provided with the particular Mas-
ter Mix product(s) to be used (e.g. 2X, 2.5X or 5X Mas-
ter Mix [with or without ROX], 50X, 40X or 25X RT or 
RT-Taq solutions etc., the μM concentration of the ROX 
stock solution and the mM concentration of the MgSO4 
or MgCl2 stock solutions provided in the particular kit be-
ing used). [Upon reset, the P-Q program defaults to using 
ABI’s One-Step Master Mix Reagents Kit which includes 
a 2X Master Mix and a 40X RNasin-RT solution].
The power of foresight allows one to choose the extent 
of dilution which is most aptly suited to the target set of in-
terest during each Test Plate analysis. Using conditions tai-
lored specifically to any pre-knowledge of the relative abun-
dance of each of the target transcripts is a crucial stratagem 
to harness/employ during Test Plate designs. If the tested 
Stock I dilution range is not sufficiently wide, one may miss 
the opportunity to have assessed a wider [valid] dynamic 
range on the final experimental sample plates; this can be 
the consequence of not exploring more extensive dilution 
series’ on one’s Test Plates. Conversely, using too wide of 
a Stock I dilution range on a Test Plate can make it hard to 
identify the Stock I dilution(s) at which certain qPCR target 
signal strengths begin to die off. Also, it is important for 
investigators to know when it is prudent to use either me-
dian dilution ranges or differential Stock I dilutions (on a 
per target basis) when the targets of interest are thought to 
differ greatly in relative abundance (in Stock I) with respect 
to one another when being assessed on the same Test Plate. 
Sometimes running more than one Test Plate may be neces-
sary to get all the preliminary information you need.  
The P-Q program has been largely created to use pre-
formulated, commercially-available Master Mixes (in ef-
fort to maintain the “high-throughput and reproducible” 
philosophy so prevalent in the qPCR, micro-array, mass-
array and proteomics worlds today), but it can also be used 
in conjunction with self-made/custom Master Mix for-
mulations if one is able to translate such custom mixes in 
[relative or direct] terms of one of the commercial qPCR 
mixes already included among those whose assembly is 
automatically spelled out by the program. The pertinent 
Master Mix parameters are entered into “UMES.xls” file 
cells G31 and G32 (and additionally into cells K197, L199 
and N202 for other required Stratagene Master Mix pa-
rameters). Final prepared qPCR reaction parameters (e.g. 
sample volume used per each prepared qPCR reaction) are 
entered into cells N134, N136 and N138 of the “UMES.
xls” file and into cell ranges H87:K98 or F109:K120 of the 
“Questionnaire.xls” file (singular qPCR reaction compo-
nent entries are available there as well). Differential use 
of MgSO4 and/or MgCl2 on a per-target basis is also ad-
justable (in terms of Invitrogen Master Mix) - inside the 
“zPrintouts.xls” file (cells AR15, AW15, AR24, BA23, 
BA24, AR33 and AR42 of the “TP MM”, “SP MM” and 
“NRC MM” sub-worksheet ‘tabs’ within that file). In addi-
tion, ROX usage is also adjustable in various regions of the 
“zPrintouts.xls” file for some of the various Master Mixes 
shown. Transposing specific formulations of one Master 
Mix in terms of another Master Mix (those not included in 
the program) is up to the investigator as it is understand-
able that the program cannot include or account for all 
possible Master Mixes. And, in the event that one enters 
aThe term “in-well,” when applied to the dilution of a nucleic acid sample, refers to how much each sample has incurred post-DNase treatment for One-Step 
qPCR samples (or post resolubilization if no nuclease treatment is used) and post RT reaction for Two-Step samples by the time the samples actually reside 
in the final reaction mixture in a well on a reaction plate (or indeed, final reaction tube). The in-well dilution of a sample is thus the combination of the post-
DNase (or post RT) dilution of samples (i.e. 1:5 or 1:10 dilution of all samples), the dilution each sample undergoes to attain the ng/μL concentration and 
non-inhibitory dilution that works for the target which requires the most ng sample per μL reaction, and the dilution each sample incurs merely by being 
placed into the reaction itself. These are basic things that need to be acknowledged for they too often go unnoticed or unaccounted for. P-Q keeps track of all 
of this for each sample. [The proportion that sample volumes are per each final qPCR prepared reaction volume is also an essential part of determining the 
final in-well dilution incurred by each of your samples either post-DNase or RNase treatments (for One-Step qPCR) or from RT reactions on (for Two-Step 
qPCR). Typically, our samples are 0.24 of each qPCR reaction (e.g. 7.2 μL per each 30 μL qPCR reaction prepared). Yours may differ from that – but, be sure 
to take this into account when calculating the overall final in-well dilutions of your own samples if not using P-Q].
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impossible primer or probe amounts, the maximal allow-
able amounts for primers and/or probes is shown within 
specific regions of the “zPrintouts.xls” file to guide users 
to precise and correct set-ups. 
PrEXcEL-Q sample number limitations
Auxillary program file, “01AuxSmplFile.xls” allows 
an infinite number of RNA samples to be processed in a 
One-Step qPCR application. And, while only 60 samples 
are allowed at a time for Two-Step qPCR (where RT re-
action formulations are to be shown by the program), if 
cDNAs have already been made, P-Q can again be used 
to handle an infinite number of samples. A maximum of 
7 targets is allowed at a time. For more than 7 targets, use 
“Quick Mode #6” or merely use multiple instances of the 
program (renaming the master folder each time it is to be 
copied and the program used for another set of targets). 
The accompanying P-Q user’s manual can be consulted 
for more detail on key aspects of the program.
GOAL #1:  create a test (validation) Plate using “stock I”
The program suggests the use of a “Stock I” mixture (a 
mixture of a portion of each of your experimental samples) 
to serve as the serially-diluted sample used on the Test Plate, 
and doubly, as the material from which all standard curves 
will be made on your final experimental plates. To justify this 
approach, several general assumptions have been made:
Theory: “Stock I” will behave most identically to 
your actual samples since it is made of the very samples 
themselves. 
Theory: Purified plasmid constructs cannot be as-
sumed to behave similarly to tissue, cell or other biologi-
cally-derived nucleic acid samples unless they are spiked 
into experimentally similar samples early on and subjected 
to the same regimen of nucleic acid isolation/purification 
as the experimental samples have been. In addition, many 
plasmid constructs are not currently available. Nonethe-
less, the genesis of all sample, standard and/or calibrator 
isolates should be kept as similar as possible; an approach 
that is accepted as a “good science” practice in general. 
All qPCR methods benefit from the use of similarly-pre-
pared samples and the use of standard curves that are 
truly suited to and/or substantively representative of the 
samples being studied. Standards can, however, also be 
made from any appropriate amplifiable nucleic acid mate-
rial but should be used only for samples which have all 
been prepared identically (10, and a March 01, 2006 Drug 
Discovery and Development Webcast @ http://www.ddd-
mag.com/reliability-of-qPCR-data.aspx).
Theory: To be safe, it should always be assumed that 
all samples contain unintended carryover material(s), mol-
ecules or chemicals, some of which are inhibitory to the 
RT phase, Taq (PCR) phase, or both phases of the qPCR. 
Every different nucleic acid isolation method and sample 
type from which nucleic acids are isolated has the poten-
tial to introduce inhibition of some kind. Also, it should 
never be assumed that column purification methods used 
for nucleic acid sample isolations are more effective at 
eliminating inhibitory materials. Some of the worst qPCR 
inhibition we have observed occurred among samples iso-
lated using column methods (1:3000 CJ, 1:2000 MC; Dr. 
C. Johnson and M. Carruthers, unpublished results), but, 
as well, some of the least inhibition we have seen occurred 
among samples isolated/purified using column methods 
(1:50 SC, 1:150 ZP, 1:30 NAL, 1:60 EB; Dr. B. Sponseller 
and S.K. Clark, Dr. Z. Liu, Dr. N.A. Levy and Dr. E. Be-
hlke, unpublished results).
For Absolute qPcr, the ng/μL values generated by 
P-Q can be readily converted to copy numbers by us-
ers whenever the relationship between absolute standard 
material and copy number per unit volume or unit tem-
plate mass is known. Nevertheless, evaluation of Stock 
I material (made of the samples) is still necessary in or-
der to provide the user with the exponential amplification 
(EAMP) values for each target when amplified from sample 
material since EAMP values for these same targets when 
amplified using absolute template material (e.g. purified 
plasmid(s) containing target insert(s)) will differ (usually 
be higher) due to either purified absolute template ma-
terial harboring less inhibitory material, or due to plas-
mids (in general) often amplifying by PCR with higher 
efficacy than other target template varieties on account 
of geometry alone. So, when one knows the concentra-
tion of absolute template material in terms of both ng/μL 
and copies/μL, and after one has compared the absolute 
template’s ability to amplify for a target with that of a 
sample or Stock I’s ability to amplify for that same target 
(wherein all such measurements have been made within 
the valid, non-inhibitory, LOG-linear-amplification-capa-
ble, high-efficiency-of-amplification Stock I and absolute 
template dilution regions), the magnitude of difference 
between these two evaluations of the same target yield an 
attenuating factor which is entered directly into P-Q for 
each different target standard curve graphic as shown in 
the program’s “zPrintouts.xls” file’s “Qspecs” worksheet 
tab. Attenuating factors (for each different target) are en-
tered into “Qspecs” cells: AH22, AU22, AH63, AU63, 
AH103, AU103 and AH147. Once you have calculated 
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how many copies of target there are per μL qPCR reac-
tion for both Stock I and absolute template material, the 
calculated number of target copies/μL contained at each 
Tier ng/μL dilution of Stock I material are entered into 
“Qspecs” cells: AI27, AV27, AI68, AV68, AI108, AV108 
and AI152 for each different target. “Qspecs” cell range 
AX40:BJ79 provides the entire network for up to 7 tar-
gets for exacting these calculations. Only one valid target 
Ct observation per absolute template material in terms of 
copy number/μL qPCR reaction paired with one similarly 
valid observation for the same target using Stock I mate-
rial is necessary to estimate copy numbers of that target 
in unknowns/samples. As a result of these “Qspecs” en-
tries, the program shows the investigator the equivalent 
ng/μL for each standard to which the absolute template 
material for each target should be diluted to kinetically 
encompass the same valid, LOG-linear-amplification-
capable dilution range exemplified by each target when 
amplified from within sample or Stock I material. The 
equation we developed to calculate each target’s attenua-
tion factor is as follows:  
Equation 1: ((Sample-derived template target’s EAMP
ob-
servedCt) / (Absolute template target’s EAMP
observedCt))*(Sample 
derived template ng/μL evaluated in-well/Absolute template 
ng/μL evaluated in-well) = Attenuation factor (the factor by 
which absolute template is diluted to exactly/kinetically 
mimic sample-derived Stock I for a specific target)
Finally, it logically follows that Stock I-attenuated ab-
solute template (plasmid) mixtures would use the same 
260nm value as the Stock I mixture itself (e.g. entered as 
a ‘surrogate/stand-in value’ into “UMES.xls” file cell J1). 
This is a rarely used, but helpful P-Q feature.
Use of exogenous stock I mixtures. Made of (newer 
or older) samples other than the ones being evaluated 
presently, is also possible. In such cases, the investiga-
tor will enter the actual or calculated 260nm absorbance 
reading of the exogenous Stock I material directly into 
“UMES.xls” file cell J1 and proceed to use the program 
as usual. Along with the desired prerequisite that exter-
nally-introduced Stock I solutions be comprised of mate-
rial that has experienced the same genesis as the experi-
mental samples have (and for which it will be used as a 
measure), it also becomes clear that it is intuitively best 
to dilute such Stock I solutions to the average ng/μL of 
what a Stock I solution would be if the samples them-
selves had been mixed equivolumetrically - in “normal 
Stock I fashion.” Assuming that the “Stock I” idea will 
be pursued (one which we are avid proponents of for nu-
merous, first-hand experiential reasons):
After all required entries have been made (within the 
“Questionnaire.xls” and “UMES.xls” files), the next step 
toward arriving at the Test Plate set-up is to decide what 
dilution range of the “Stock I” material is best suited to the 
particular genes or transcripts of interest. This is accom-
plished by using what is known about the expected relative 
abundance of the targets of interest in conjunction with the 
Ctrl Shift A Macro of P-Q to calculate the most suitable 
dilution series of “Stock I” to be tested across each of the 
different targets. Up to 7 targets per Test Plate are allowed. 
Typically, dilution ranges of full-strength to 1:1,000 are ap-
propriate for most LCM-derived samples (of 25-500 cells per 
original sample isolate), full-strength to 1:10,000 dilution for 
non-LCM-derived rare targets or transcripts, full-strength 
to 1:50,000 or 1:100,000 for medium-abundant transcripts, 
full-strength to 1:1,000,000 for “normally-expressed” tar-
gets or transcripts, and full-strength to 1:5,000,000 for 
abundant targets. (For those of you who use RIBO 18S or 
RIBO 16S as a reference gene or organismal identifier, you 
will notice that, even at an in-well dilution of 1:5,000,000 
or even greater, these signals are still reliably measurable. 
Imagine diluting 1 μL of sample into 5, 10 or 20 Liters of 
water and still getting robust Ct values! This speaks well for 
the incredible sensitivity of qPCR in general). 
But, to continue, and to repeat a few important things, 
after one has successfully completed all of the required 
maneuvers described up to this point, and has 1.) Entered 
the appropriate Master Mix parameters into cells G31 and 
G32 (and additionally into cells K197, L199 and N202 for 
other required Stratagene Master Mix parameters if us-
ing a Stratagene Master Mix) or has run an auto-Master 
Mix parameter insert Macro (e.g. the two Master Mix pa-
rameter auto-insert Macros are Ctrl Shift D for Invitrogen 
Master Mix and Ctrl Shift O for BIO-RAD Master Mix), 
2.) Entered the required target names and primer-probe 
[nM]-use information along with the target (‘t’) or refer-
ence gene (‘h’) designation for each within “UMES.xls” 
cell range J126:K132, 3.) Decided on the Test Plate Stock 
I dilution range, and has entered the desired appropriate 
upper Stock I dilution limit value in “UMES.xls” file cell 
M28, and 4.) Has activated Macro Ctrl Shift A, this is all 
immediately followed by running one of the three main 
user parameter introduction Macros:
• Ctrl F  for One-Step qPCR (either “Questionnaire.
xls” file-based or not)
• Ctrl x  for Two-Step qPCR (either “Questionnaire.
xls” file-based or not) then immediately double-
check “UMES.xls” cell region O134:U138 for helpful 
messages.
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• Ctrl w for LCM-based qPCR (use default One-Step 
settings, or use a “Questionnaire.xls” file-based or 
non-“Questionnaire.xls” file-based Two-Step ap-
proach if cDNAs are to be made and 260nm values 
of the LCM RNA samples are known - or good esti-
mates thereof at least). Some good approximate fig-
ures to keep in mind (for mammalian cells): one cell 
contains ~6.16 pg DNA, ~20 pg total RNA, and ~0.5 
pg mRNA.
Next, if pursuing Two-Step qPCR, the investigator 
first sets up the sample RT reactions as acknowledged 
(and spelled out) by the appropriate printouts within the 
“zPrintouts.xls” file, and then sets up and runs the Test 
Plate according to the 3 printouts describing the Test Plate 
set-up in the “zPrintouts.xls” file, or, if the investigator is 
pursuing One-Step qPCR or One-Step LCM-qPCR (where 
RT reactions are not undertaken in a preliminary, separate 
step), the user sets up and runs the Test Plate according 
to the 3 printouts describing the Test Plate set-up in the 
“zPrintouts.xls” file.
GOAL #2:  Use the test Plate ct values to determine the 
non-inhibitory, LOG-linear-amplification-capable, high-
est-efficiency-of-amplification ranges for each target
This is accomplished using the “Point Selection Pro-
cess” within files “TestPlateResultsAnalysis2006.xls” 
and “TestPlateResultsAnalysis2006b.xls” (after introduc-
ing the Test Plate Ct results into “UMES.xls” cell range 
B197:H208 and running the Macro Ctrl Shift C). Once the 
Point Selection Process is completed, and after introduc-
ing your final choices/selections/settings into the program 
using the universal system updating Macro, Ctrl Shift Z, 
one then checks for any error messages (in cells F3, E129 
or BE9 of the “UMES.xls” file) and proceeds to correct 
them by either altering/correcting user input values, ad-
justing standard curve ranges, adjusting the “Sample Aim-
ing Device” (in “UMES.xls” file cell range AX12:BK38) 
- all in conjunction with the strategic use of system-cor-
rective/update Macros: Ctrl Shift Z mainly, but also Ctrl 
y, and Ctrl Shift N for certain Two-Step changes, and Ctrl 
Shift T for LCM-qPCR related changes, etc. All Two-Step 
methods default to no more concentrated than 1:50 in-well 
dilutions as the starting point for all standard curves for 
initial set-ups, so care should be taken to remember this 
and make your final desired adjustments after entering and 
processing Test Plate Ct values for Two-Step qPCR set-
ups. The “Comprehensive Error Messaging Board” within 
“UMES.xls” file cell range J204:S227 lets the investigator 
know the source of all system errors (if any), and how to 
correct them.
GOAL #3:  Address any “Error” messages within the 
program
Once “OK” is received in the Error Messaging regions 
(in cells F3, E129 or BE9 of the “UMES.xls” file), you may 
want to prepare extra “Stock I” to use for additional stud-
ies (which can be accomplished by adjusting the value in 
cell F2 of the “UMES.xls” file and running Ctrl Shift Z, 
then check for error messages again, and re-check your 
plate drawings and your manual sample and standard vol-
ume requirement calculations to be sure your entries into 
cells F55 and F58 of the “UMES.xls” file are indeed appro-
priate (entering a little extra is always advisable). Update 
any changes with the appropriate Macro (again: Ctrl Shift 
Z mainly, but also Ctrl y, Ctrl Shift N for certain Two-Step 
qPCR-related changes, and Ctrl Shift T for LCM-qPCR 
related changes).
GOAL #4:  Attain your final sample plate and NRC/
NAc plate set-ups
Run Ctrl y and Ctrl Shift Z one last time for good 
measure, and then proceed to identify and printout the ap-
propriate pages within the “zPrintouts.xls” file and set up 
your final plates and NRC/NAC plates accordingly.
commercially-available qPcr Master Mix set-ups 
spelled out directly by PrEXcEL-Q. ABI Two-Step 
Master Mixes (Two-Step TaqMan and SYBR-based Mix-
es), ABI One-Step Master Mix Reagents kit, Invitrogen 
SuperMix with UDG, Invitrogen One-Step SuperMix, 
Qiagen One-Step Master Mix, BIO-RAD One-Step iS-
cript Mix, Stratagene Brilliant One-Step Master Mix, 
and Stratagene’s Full-Velocity One-Step Master Mix. 
Any other Master Mix set-ups can be inferred from or 
are implicit within the formulations of one or all of those 
already spelled out by the program; e.g. be able to inter-
pret/translate what the given P-Q set-ups mean in terms 
of the Master Mix you are using if it is different from the 
ones automatically spelled out by the program. Correlate 
SYBR-based mixes are implicit in each different compa-
ny’s P-Q Master Mix printout. One can also use the Mas-
ter Mix set-up numbers generated by P-Q as a guide to 
use self-formulated Master Mixes as well. Pre-prepared 
commercial kits exist which do not directly fit the output 
format of P-Q, but, their use, with some inductive input 
from the investigator, can be deduced via mathematical 
analogy from the various Master Mix set-ups already 
solved by the program. 
Appropriate mind-set when using PrEXcEL-Q. 
You will notice that the proper use of this program re-
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quires that the user works in a “projective” manner in 
which the final plate set-ups are envisioned at the same 
time the Test Plate parameters are being established (the 
beginning and end of the entire assay is in the mind of the 
user from the very outset; drawings of all desired plates, 
and manual approximate calculations of entire sample/
standard needs are important for the investigator to al-
ready have in hand before using the program). The entire 
set-up from the Test Plate to the final plates and NRC/
NAC plates are all calculated at the same time to check 
early on if there will be a problem with running short on 
sample, standard or Stock I material throughout the en-
tire run. It also informs the investigator how much Master 
Mix, primers and probes will be needed to complete the 
entire procedure at hand and thus allows one to preview 
reagent needs before each particular entire set-up in order 
to avoid ‘false starts’ and to afford one the opportunity to 
place any orders for anything that may be in present short 
supply according to what is pointed out by the program in 
advance. The program tells the user whether or not there 
is enough of each sample, standard or Stock I material to 
finish the entire study in one cohesive fell-swoop. Doing 
the entire assay in one shot is also the only approach that 
can most fully guarantee scientific consistency through-
out each entire qPCR endeavor. After Test Plate analysis 
and Test Plate Ct introduction to the program followed 
by the Point Selection Process, the program figures out 
the entire Master Mix and primer/probe needs for all final 
plates and NRC/NAC plates - and this can sometimes add 
up to 14 or 15 plates worth of Master Mix to be prepared 
all at once - but there is no better way to maintain data 
consistency than by using a common Master Mix pool 
for all reactions whose final Ct values are to be weighed 
with and amongst one another in effort to gain truly in-
formative Ct values for generating meaningful relative or 
absolute qPCR data. Liquid handling robots are a blessing 
- get one or two if you can. Or, limit yourself to setting 
up only 2 or 3 plates at a time. We often do 14 plates at 
once - which typically takes one operator about 24 to 28 
hours straight (manually, without liquid-handling robot-
ics). Taking it in smaller pieces is better - but the Master 
Mix used on all such final sample plates should be the 
exact same pool.
GOAL #5:  Process your qPcr results using your own 
preferred approach
Creating custom Excel files based on the Pfaffl (or 
“EAMP
ΔΔCt”) Method seems to work the best for targets ex-
hibiting near ideal amplification efficiencies (e.g. 100% ± 
15%). Also, remember that technical replicate Ct values 
should not deviate more than ~0.5 Ct units from one an-
other in order that statistical analyses of qPCR data retain 
ample rigor. 
DIscUssION
The P-Q approach to qPCR assumes, stresses, and 
requires consistency in all facets of nucleic acid sample 
preparation. This “good science” practice maximizes 
experimental sample similarity and, therefore, sample 
inter-comparability. Such facets are:  a) Method of RNA 
or DNA isolation, purification and storage; b) DNase or 
RNase treatments and reverse transcription (RT) reaction 
formulations; c) Dilutions of all samples beyond the point 
where inhibition of RT and/or PCR is expected; d) Use of 
all samples, per qPCR target (outside RT- and PCR-inhibi-
tory ranges) at the same ng/μL concentration within the 
valid, high efficiency, LOG-linear-amplification-capable 
dilution range per each sample (per target within each 
sample); e) Good primer and probe designs (hopefully 
designed using programs containing algorithms that are 
able to successfully identify and eliminate false priming 
regions from consideration).
P-Q re-introduces our (2004) idea of “Stock I” which 
can be a single sample, or a mixture of some or all of the 
samples involved in a qPCR study (19). This provides in-
vestigators a plentiful reservoir of material that is the best 
overall representative of how each individual sample will 
behave during RT and/or PCR, and which is used for pre-
liminary target Test Plate analyses as well as the standard 
curve material for all final plates. Since all samples can 
contribute to Stock I, no single sample is exhausted prior 
to qPCR. NOTE: any standard curve can be generated ‘af-
ter-the-fact’ in cases where Stock I proves to be “anemic” 
or insufficient for a particular target or targets. Samples 
Interesting note: qPCR target amplification Efficiencies <100% appear to be stable in most cases. Even if your oligo (primer, primer-probe) sets are the “best” 
design they can be, they often exhibit less than optimal efficiency – but are curiously consistent in that regard. Efficiencies >100% indicate either some form 
of RT and/or PCR inhibition wherein the more concentrated sample(s) (in a progressive dilution series of that sample or sample mixture) exhibit higher Ct 
values than they should – given the behavior of the lesser concentrated sample Cts as the serial dilution progresses, or that truncated (partially degraded) target 
transcripts are generating additional signal arithmetically from cycle to cycle, as opposed to geometrically − in a “two-to-the-n” (2n) sense (21).
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with ample signal for such targets are revealed individu-
ally on the final plates − after which custom Stock I sample 
mixtures can be formulated and standard curves run.
Always try to use maximal sample amounts in each 
Master Mix - why not? (Especially if you have plenty of 
each sample). This helps stave off the Monte Carlo effect 
as well. P-Q defaults to using sample maxima within each 
different company’s Master Mix. e.g. 7.2 μL/30 μL reaction 
for Invitrogen One-Step Master Mix or 7.8 μL/30 μL reac-
tion for ABI and BIO-RAD One-Step Master Mixes (e.g. as 
initially inserted by the Ctrl Shift D or Ctrl Shift O Master 
Mix parameter auto-insert Macros, respectively; param-
eters which are still adjustable by the user afterwards).
On account of what P-Q does, there is theoretically no 
need to correct for “sample loading” (using reference genes) 
once you have proven you are working in the valid, LOG-
linear-amplification-capable dilution range for each of your 
qPCR targets. After P-Q calculates sample dilutions out-
side of their expected inhibitory ranges, it then calculates 
the same ng/μL sample per each different target per each 
final target reaction - all within the valid, non-inhibitory, 
LOG-linear-amplification-capable, high efficiency range 
for each target. Therefore, due to dynamically sound, equal 
sample loading on a per target basis, the use of reference 
genes becomes theoretically unnecessary; and much of our 
recent data seems to bear this out. But, a note of caution 
here: although this is a time-saving and high-throughput 
idea, it still represents a radical departure from common 
qPCR practice. Further, in the event that RNA sample 
spectrophotometer or NanoDrop readings are slightly off 
(due either to user error or to contaminating genomic DNA 
contributing to initial RNA sample readings), it is still wise 
to run one or two appropriate (validated) reference genes 
and compare final quantitative results with and without 
figuring them into the calculations. If the same results are 
apprehended either way, three observations come to light: 
a) the reference gene(s) are apparently stable; b) the use of 
reference gene data normalization becomes unnecessary in 
such cases; c) the P-Q method regarding this point appears 
to be valid. However, of greatest importance, and vital to 
allowing qPCR to generate potentially biologically rele-
vant and/or meaningful gene expression data, is the critical 
need for investigators to require of themselves to use only 
high quality RNA (assessed for integrity beforehand) ex-
hibiting 260nm/280nm purity ratios of 1.8 or greater, before 
using it in the assay to begin with (1).
comprehensive list of PrEXcEL-Q Macros
Note: there are many Macro sub-commands buried 
within the main Macros in P-Q. Virtually every combina-
tion of letter and Ctrl key and/or Ctrl-Shift keys has been 
assigned to a Macro in the creation of this program. But, 
there are only a handful of these commands that you, the 
user, need be aware of. Even though the Macros have been 
explained to some degree already, a comprehensive listing 
and description of what they each do is surely also helpful, 
so here is the list:
Ctrl Shift F is the major Starting Macro that is used 
to globally assimilate all initial user parameter entries 
into the system within the “Questionnaire.xls” and the 
“UMES.xls” files. Activate this command from within the 
“UMES.xls” file when ready. It is usually the very first 
command you will use for all One-step qPCR modes.
Ctrl Shift D is used to insert optimal parameters for us-
ing Invitrogen SuperMix™ Master Mixes (775 nM prim-
ers, 150 nM probe and 5.5 mM final [MgSO4] or [MgCl2] 
and 7.2 μL sample per 30 μL reaction size). Activate this 
command from within the “UMES.xls” file. LCM-qPCR 
mode defaults to this mix.
Ctrl Shift O is used to insert optimal parameters for 
using BIO-RAD iScript™ Master Mixes (925 nM prim-
ers, 150 nM probe and 7.8 μL sample per 30 μL reaction 
size). Activate this command from within the “UMES.
xls” file.
Ctrl Shift E is activated from within the “UMES.xls” 
file and is used to correct DNase- or RNase-treatment-re-
lated errors in the “UMES.xls” file. This command will 
not correct mistakes in all situations e.g. where a sample or 
samples are too concentrated to receive ample DNase- or 
RNase-treatment; in which case(s) you should dilute such 
samples so their calculated 260nm values are ~0.6 (@ 1:50 
dilution). 0.301029996, which = LOG
10
 of 2, is the most 
reliable reading on a spectrophotometer − as wrought out 
by Beer’s Law: Absorbance = LOG
10
(Io/It) = εcb. Absor-
bance readings are most accurate when It is ~50% of Io 
(e.g. when A = ~0.301), so, ideally, you would like all of 
your spectrophotometer sample absorbance readings to 
be as near ~0.301 as possible in all situations. In practice, 
readings between 0.05 and 1.0 are generally useful as they 
fall mostly within the linear range of a standard spectro-
photometer’s ability to interpret sample transmittance. For 
P-Q, 260nm samples reading above 0.6 (@ 1:50 dilution) 
should be diluted so that they would be calculated to read 
no more than 0.6 (@ 1:50 dilution), however, this is not 
written in stone and you can ignore this if you wish. Gen-
erally, we urge people to dilute samples with readings of 
0.8 or higher (@ 1:50 dilution) to ½ strength so they will 
not trigger error messages in the program (associated with 
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insufficient DNase- or RNase-treatments). The NanoDrop 
device is exempt from the limitations spelled out above in 
that it employs an entirely different (LED and fiber-op-
tic-based) technology than most standard spectrophotom-
eters; it is thus, not prone to the same ‘non-linearity’ that 
spectrophotometers are prone to.
Ctrl x is used to run both Ctrl Shift F, hidden Macro 
Ctrl Shift J and Ctrl Shift N back-to-back to initiate P-Q 
into Two-Step qPCR Modes #2 or #4. Activate this com-
mand from within the “UMES.xls” file. (Ignore the Ctrl 
Shift J Macro individually).
Ctrl Shift N is used after Ctrl x to update any Two-Step 
qPCR-related changes which affect RT and cDNA reac-
tions. This command also auto-finds the required cDNA 
volumes.
Ctrl y is used to attain non-excessive Master Mix prepa-
ration amounts; run at any time, always follow it with Ctrl 
Shift Z so your parameter adjustments can be assimilated.
Ctrl Shift Z is the Universal System Update Macro which 
can be run anytime during use of the program. If you feel 
your parameters have not been assimilated or incorporated 
into the program, this Macro always updates/assimilates/in-
corporates all adjustments you have made to the system at 
any time. (Hidden Macros Ctrl Shift X, Ctrl Shift Q & Ctrl 
Shift M are all a part of the Ctrl Shift Z Macro).
Ctrl Shift A is used to automatically calculate evenly-
spaced Stock I progressive serial dilutions for your Test 
Plate across the range you specify the upper limit for by 
the value you enter into cell M28 of the “UMES.xls file.” 
The M28 value indicates the highest dilution of Stock I 
solution tested on your Test Plate, and this value also rep-
resents your “in-well” dilution of that sample (post-DN-
ase or RNase-treatment but including the dilution speci-
fied in “UMES.xls” file cell I13). Activate this command 
from within the “UMES.xls” file when ready. Follow this 
always with Ctrl Shift Z. (This Macro relies on region 
IG11:IT30 of the “UMES.xls” file for its “double-LOG 
plot” functionality). Notice, in the “zPrintouts.xls” file, 
within the Test Plate tab (1st sub worksheet tab), that the 
ideal Ct values you should expect from your chosen Stock 
I dilution series for your Test Plate are already spelled out 
in cells D1 through M1. Deviations from these ideal Ct 
values of course indicate other than 100% efficiency of 
your qPCR reactions. You can always calculate what any 
Ct would’ve been had its governing reaction occurred at 
100% efficiency by the equation: Ct
observed
 × LOG2(EAMP) 
= Ct
@100%Efficiency
 (assuming no inhibition is involved and 
that you are truly working within the LOG-linear-ampli-
fication-capable range of the qPCR assay). Exponential 
Amplification or EAMP = (E + 1). Efficiency of Ampli-
fication or E = [10(-1/m) - 1], where “m” is the slope of a 
qPCR target’s standard curve when Ct (or CP) is plot-
ted vs. LOG
10
 of: sample dilution factor, template input 
or target copy number (2). Activate it from within the 
“UMES.xls” file.
Ctrl Shift C is used to prepare the “TestPlateResults-
Analysis2006.xls” files for use. Activate this Macro only 
after you have run your Test Plate and have entered your 
Test Plate Ct values into the appropriate cells in region 
B197:H208 of the “UMES.xls” file. Activate this Macro 
from within the “UMES.xls” file. Follow this always with 
Ctrl Shift Z.
Ctrl Shift B is used during the “Point Selection Pro-
cess” to incorporate each of the point selections you make 
(in effort to uncover/reveal the LOG-linear-amplifica-
tion-capable ranges for each of your targets within the 
particular Stock I tested) while working within the “Tes-
tPlateResultsAnalysis2006.xls” file. Activate this Macro 
from within the “TestPlateResultsAnalysis2006.xls” file 
each time your point selections have been changed. Ctrl z 
is used during the “Point Selection Process” while work-
ing within the “TestPlateResultsAnalysis2006b.xls” file 
to automatically have P-Q select your valid, LOG-linear 
standard curve ranges based on your entries. Activate this 
Macro from within the “TestPlateResultsAnalysis2006b.
xls” file. Follow this with Ctrl Shift Z.
Ctrl q is used during the “Point Selection Process” while 
working within the “TestPlateResultsAnalysis2006b.xls” 
file. Activate this Macro from within the “TestPlateResult-
sAnalysis2006b.xls” file to incorporate your own standard 
curve starting and ending dilution choices (which you type 
into CC8 and CC9 and so on, of the “TestPlateResults-
Analysis2006b.xls” file). Follow this with Ctrl Shift Z.
Ctrl e is used during the “Point Selection Process” while 
working within the “TestPlateResultsAnalysis2006b.xls” 
file. Activate this Macro from within the “TestPlateResult-
sAnalysis2006b.xls” file to incorporate your own standard 
curve dilution factor choices (which you type into CC10 
and so on, of the “TestPlateResultsAnalysis2006b.xls” 
file). Follow this with Ctrl Shift Z.
Ctrl Shift G uses the “Sample Aiming Device” to auto-
matically calculate the safe dilution of all of your samples 
to avoid inhibition. But, one “weak” sample here (e.g. a 
sample with inordinately lower concentration than the 
others) can ruin it for the rest of the samples here - forc-
ing them to be diluted out further than necessary all on 
account of one “bum” sample. Activate this Macro from 
within the “UMES.xls” file when it is prudent to do so. 
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Allow yourself the discipline to refuse the use of “anemic” 
(low-concentration) samples at times. Re-isolate.
Ctrl Shift W uses the “Sample Aiming Device” to al-
low you to attain your own desired Tier 1 ng/μL concen-
tration. You would activate this Macro after entering your 
desired Tier 1 ng/μL value into cell BE14 of the “UMES.
xls” file (in the “Sample Aiming Device” region). Activate 
this Macro from within the “UMES.xls” file when ready.
Ctrl Shift U (is the “Full Strength Sample Option”) 
which uses the “Sample Aiming Device” to allow you to 
attain a Tier 1 ng/μL concentration which is equal to your 
most concentrated standard ng/μL value. Activate this 
Macro from within the “UMES.xls” file whenever desired 
(i.e. for LCM-qPCR).
Ctrl w is used to run both Ctrl Shift F and Ctrl Shift 
H back-to-back to initiate P-Q into LCM One-Step qPCR 
Mode #5. Activate this command from within the “UMES.
xls” file when ready. (In other words, the Ctrl Shift H Mac-
ro, by itself, can be ignored entirely - which is analogous to 
Ctrl Shift J for Two-Step qPCR above).
Ctrl Shift T is used to update/incorporate any changes 
made to the “LCM Sample Parameter Adjust Region” in 
cell range L185:N197 during the use of P-Q for LCM-re-
lated qPCR (Mode #5). Activate this Macro from within 
the “UMES.xls” file.
Ctrl i is used to update the “zPrintouts.xls” file at any 
time the user feels her/his set-up has not been updated for 
printouts. Ctrl Shift Z always runs the Ctrl i Macro as part 
of itself, so do not worry about running Ctrl i if you have 
just run Ctrl Shift Z. Activate this Macro from within any 
file at any time.
Ctrl m is used to clear the “zPrintouts.xls” file at any 
time. Activate from within any file.
Ctrl Shift S is used in conjunction with the “Quick Ac-
cess” function in “UMES.xls” file cell region F64:G70 to 
quickly attain one’s desired standard curve dilutions by 
merely selecting the starting dilution and serial factor for 
up to 7 target standard curves. This Macro automatical-
ly adjusts the values in the two ‘TestPlateResultsAnaly-
sis2006.xls’ files to attain your “Quick Access” param-
eters. Activate this Macro from within the “UMES.xls” 
file, and always follow it with Ctrl Shift Z.
Ctrl Shift V is used to trim the added residual factor 
of 0.000000001 off the values incorporated into the ‘Test-
PlateResultsAnalysis2006.xls’ files as the result of running 
Ctrl Shift S or Ctrl Shift P. Activate from within “UMES.
xls,” follow it with Ctrl Shift Z.
Ctrl Shift P is used in conjunction with cell region F59:
H61 near the “Quick Access” region in the “UMES.xls” 
file that looks like the following (Fig. 3):
To quickly attain the same starting dilution factor and seri-
al progressive dilution factor for all target standard curves, 
type in your desired starting dilution into “UMES.xls” cell 
G61 (e.g. “50” in the above picture) and your desired serial 
progressive dilution factor into “UMES.xls” cell H60 (e.g. 
“3” in the above picture), then run Ctrl Shift P. Activate 
this Macro from within the “UMES.xls” file, and always 
follow it with Ctrl Shift Z. 
The Ctrl r Macro resets the “Questionnaire.xls” file, 
inserts an “m” into “Sample Aiming Device” cell BB29, 
and inserts “10” into cells F55 and F58 of the “UMES.xls” 
file. Activate this Macro from within the “UMES.xls” file 
whenever appropriate. This Macro is already an integral 
part of the Ctrl Shift K command below.
Ctrl Shift K is the Comprehensive System Reset 
Macro used to reset the entire P-Q program. It resets all 
fields to pre-set/surrogate values (of a theoretic 7-target, 
72-sample One-Step qPCR set-up). Activate this Macro 
from within any file when you wish to start from scratch 
and/or initialize a new instance of P-Q to use for a new 
qPCR study.
Be sure to activate the exact Macro command(s) you 
intend:  e.g. “Ctrl y” not “Ctrl-Shift y” … be very accurate 
as to which Macro you activate, and when. In addition, 
if you unintentionally activate a Macro, hit the Esc key, 
return to the “UMES.xls” file, and proceed - no damage 
done (except when accidentally activating the Macro Ctrl 
a from within files other than the three “MMSetup2006.
xls” files. This Macro, if activated accidentally from with 
inside the wrong file, will require that you start over, un-
less you have already saved your changes prior to the ac-
cidental Ctrl a Macro activation.
DNase, rt and One-step vs. two-step qPcr Discus-
sion, and Opinions
With DNase treatments ... know your exact condi-
tions, and use them for each and every one of your sam-
ples preceding One-Step qPCR. This falls in line with the 
familiar seed of thought which gives rise to the philoso-
phy that ‘the more identical your samples are (e.g. make 
sure that all samples are exposed to identical pre-qPCR 
Figure 3.
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preparative methodologies), the more they can truthfully 
be viewed as things which can actually be compared with 
and amongst one another in scientifically-sound fashion,’ 
etc. But ... for Two-Step qPCR, you see that this ‘DNase-
treatment similarity philosophy’ is often abandoned in 
favor of another point of user-attainable sample-similari-
tude:  DNase treatments of RNAs destined for RT [cDNA 
synthesis reactions preceding Two-Step qPCR] are often 
not uniform at all. But, these DNase-treatments are either 
preceded or followed by dilutions which allow the same 
amount of [DNase-treated] RNA to end up in each of the 
RT [cDNA synthesis] reactions. These pre- or post-DN-
ase treatment dilutions represent the ‘normalising’ fea-
ture of Two-Step qPCR that then makes all the samples 
similar at this point - albeit on a basis of sample RNA ng/
μL concentration during RT. But, these approaches as-
sume (in addition to all RT reactions containing the same 
concentration of differentially-diluted RNA) that all RT 
reactions are not differentially sample-RNA-inhibited 
(due to each sample being diluted to a different extent 
in effort to attain the same [ng/μL] for DNase treatment 
or for RT), and that all RT reactions are formulated cor-
rectly so that each RT reaction can be expected to oc-
cur at the same RT reaction efficiency [i.e. all reactions 
converting 2 μg of RNA into 2 μg of cDNA are deemed 
100% efficient. Whereas if the reactions converted 2 μg 
of RNA into 1.6 μg of cDNA the reactions would be as-
sumed to have occurred at 80% RT efficiency, and so on]. 
Outside the notion: “But reference genes will straighten 
this whole thing out in the end anyway” ... there may 
indeed be ‘hell’ to pay here. E.g. what if each different 
target transcript is reverse transcribed with different ef-
ficiency in the presence of differential amounts of inhibi-
tory material per each differently-diluted RNA sample? 
The differential nature of these reactions depending upon 
sequence topographies, differential degradation rates of 
different RNAs and differentially-concentrated inhibi-
tory materials etc. can all collude to affect RT and PCR 
reactions, and therefore, a user’s ability to get at, and 
report, the truth. So, for those who perform only Two-
Step qPCR, how does one establish confidence (outside 
of sheer RNA sample dilutions which have already been 
shown to preclude inhibition of RT and/or DNA poly-
merase enzymes [due to either too much RNA itself or 
carry-over contaminants from sample preps]) that each 
RT reaction for each sample indeed goes off at the same 
(or acceptably similar) RT efficiency in each case - es-
pecially when one has not diluted one’s sample RNAs 
such that they each end up (in-well) diluted (post-DNase 
treatment) at least 1:50 (for column isolates) or 1:200 (for 
Trizol isolates) within the final qPCR reactions? Recall 
that these dilution thresholds (1:50 in-well, 1:200 in-well, 
etc.) when not heeded, destroy the ability of RT and PCR 
reactions to work correctly during One-Step qPCR (2). 
But, why would the RT reactions preceding Two-Step 
qPCR be exempt? There is one reason which may be 
good enough:  RT enzymes are typically used 5 to 40 
times (ABI Multiscribe RT and Invitrogen SuperScript™ 
III, respectively) more concentrated per unit volume RT 
reaction preceding Two-Step qPCR than what they are 
used at for the RT phase of One-Step qPCR. In other 
words, possibly by sheer attrition, the higher presence of 
reverse transcriptase enzyme alone may be effective in 
[overcoming RT-inhibitory factors] providing enough RT 
activity during RT reactions to maximize the efficiency 
of RT reactions preceding Two-Step qPCR in most cases; 
effectively accomplishing the same thing that increased 
sample dilutions would prior to One-Step qPCR (which 
uses as little as 0.25 Units/μL RT enzyme for first-strand 
synthesis in some cases). RT reactions preceding Two-
Step may be more resistant to inhibition on account of 
the higher (Units per μL) presence of RT enzyme than is 
used (per μL) in many commercial One-Step qPCR reac-
tion formulations. But beware: 10 Units/μL RT enzyme 
can end up crippling subsequent PCR (qPCR) reactions 
since RT enzymes (apparently even denatured) can bind 
cDNA, causing sporadic amplifications during the PCR 
phase (ABI product literature note regarding use of their 
Multiscribe™ RT enzyme).
There is also RIBO Green, which investigators can 
use to quantify cDNAs after each RT reaction to check 
each RNA sample’s efficiency of transformation into 
cDNA (25) - but, such analyses could very well invite 
other misinterpretations - so we have the tendency to 
avoid the entire debate by sticking with well-rendered 
One-Step qPCR in as many cases as possible, even 
though cDNA can last for decades in the freezer. If your 
RNA samples are extremely precious and/or limited in 
supply, by all means convert them to cDNA for longev-
ity. But, DNase treat them all identically (same volume 
of RNA per each DNase reaction - before or after which 
samples are normalized to the same ng/μL concentration) 
and subject them each to at least 3.5 to 5 U/μL of a ro-
bust RT enzyme for reverse transcription of RNA into 
cDNA (Invitrogen’s SuperScript™ II or III, Stratagene’s 
Affinity-Script™, Quanta’s qScript™, Takara’s Prime-
Script™ or BIO-RAD’s iScript™) but only after diluting 
Trizol RNA isolates at least 1:50 (post-DNase treatment) 
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and column RNA isolates at least 1:10 (post-DNase treat-
ment) to attain identical ng/μL concentrations of each 
RNA preceding reverse transcription to cDNAb. Between 
10 and 50 ng/μL RNA during RT is normally sufficient. 
Any more, and rRNA and tRNA (in addition to any un-
known inhibitory materials) can begin to impinge on the 
efficacy of the RT reactions. Following these guidelines 
allows Two-Step qPCR to reach the precision that well-
rendered One-Step qPCR already enjoys. 
Differentially tampering with RT reactions (using dif-
ferent amounts of RT enzyme per reaction, etc.) preceding 
Two-Step qPCR is a game to be avoided entirely, espe-
cially when it has been noted by some that only 5 to 10% 
of the RNA sample is converted to cDNA in their RT reac-
tions. Also, note that random pentadecamers have recently 
been advertised to be very effective primers to use for RT 
reactions; cDNA yield is apparently increased by 3-fold 
and the ability to amplify rare targets later by qPCR is 
increased by 11-fold (26). Mixtures of poly-(dT) and ran-
domers are also very efficacious and, also, serve to avoid 
“3-prime bias.”
Truly, a well-rendered Test Plate unravels many mys-
teries since it shows the user the unique inhibitory char-
acteristic of their samples as a group. Then, once this is 
known, P-Q calculates the valid ranges of dilution per 
target for each sample and standard curve, affording the 
investigator the best chance at generating Ct values that 
are truly reflective of the relative or absolute abundance of 
each target of interest.
But, again, for Two-Step qPCR proponents, this re-
quires that you have indeed, unequivocally, already estab-
lished methods of DNase treatment and cDNA synthesis 
(via RT) preceding qPCR which allow all of your sample 
RT reactions to occur at very similar efficiencies. Once 
this is ‘confidently’ attained, then “reference genes can 
straighten the rest out” … that is, if the reference genes 
themselves are reliable! (E.g. Ubiquitin, Ribosomal Pro-
tein S15, Elongation Factor-1α, [Bustin, et al.]) (10, 25-
32). Further, exogenous references or synthetic templates 
may help light the way out of the ‘unstable endogenous 
reference gene caveat’ (e.g. non-endogenous, synthetic or 
nonsense sequences spiked into samples exogenously at a 
key point during sample preparations can be used as nor-
malisers for each qPCR study) (28). Or, find a way to in-
corporate the use of expressed ALU repeats and/or STRs 
for primate qPCR normalization, or satellite sequences for 
other species, excluding birds and lizards (24). 
So, to recapitulate, be clear on your RT reaction for-
mulations: at what dilution of your RNA samples (pre-
ceding Two-Step qPCR) are your RNA samples no longer 
inhibitory to the RT reaction itself? As a rule of thumb, 
we have found a generally safe range to be 10-50 ng total 
RNA/μL RT reaction. But, this all depends on how clean 
the RNA is going into the RT reactions. Or, test the RNA 
in a One-Step qPCR application (Test Plate) to witness the 
kinetic landscape of the inhibitory phenomena first-hand, 
then use this knowledge to properly formulate your RT re-
actions preceding Two-Step qPCR. E.g. identify the Units 
of RT enzyme per ng RNA that will work without inhibit-
ing the PCR phase. One should strive to let the ‘sunlight 
shine through the reactions’ - don’t smother your reverse 
transcription reactions with too much enzyme or too 
much template.
Many of the above caveats can be avoided by perform-
ing One-Step qPCR for all RNA samples after uncovering 
the valid sample, target and standard curve dilution ranges 
by Test Plate analyses using P-Q. Wherein all RNAs are 
DNase-treated identically (same volume of RNA per each 
DNase treatment reaction [i.e. using TURBO DNase from 
Ambion/ABI]), then dilute all DNase-treated samples 1:10 
with nuclease-free water (with addition of RNaseOUT as 
part of the 1:10 dilution), then perform qPCR only after 
having run a Test Plate on a serially-diluted mixture of 
a portion of each of the samples (“Stock I”) to study the 
behavior of each qPCR target of interest over an appro-
priately-informative dilution series in order to identify the 
valid, non-inhibitory, high-efficiency-of-amplification, 
LOG-linear-amplification-capable sample dilution ranges 
for each target. Then, use P-Q to calculate the exact di-
lutions of all samples and standards and qPCR reaction 
formulations and to generate the printouts for the entire 
final set-up (again: all based on the dynamics revealed 
by the Test Plate). Finally, One-Step qPCR RT/Taq mixes 
from Invitrogen (SSIII and Platinum Taq-based), Takara 
b[The dilution each RNA incurs (to attain identical ng/μL concentrations) post-DNase but prior to RT, in our experience, should be at least 1:50 for Trizol iso-
lates and at least 1:10 for column RNA isolates, or inhibition of RT reactions prior to the PCR phase of Two-Step qPCR, and the PCR itself, may be reasonably 
anticipated]. Well-planned qPCR sample dilutions solve many ills – P-Q spells these dilutions out for the user (2).    
Miscellaneous note: Why RNase-treat DNA samples? Differential binding of reverse primer in differentially RNA-contaminated DNA samples. Remember, 
the hierarchy of nucleic acid affinity, in general, is: RNA:RNA (strongest), RNA:DNA (intermediate) and DNA:DNA (weakest).
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(PrimeScript™), BIO-RAD (iScript™) and Stratagene 
(Affinity-Script™ Brilliant™) are all superb in allowing 
One-Step qPCR to reach its zenith.
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APPENDIX 1
Preliminary Important Definitions and Clarifications
Being clear on the following things will help you to use 
PREXCEL-Q as intended:
qPcr refers to “quantitative real-time PCR” which 
has also been called “QRT-PCR,” “RT-QPCR,” “RT-RT-
PCR,” “real-time relative or absolute quantitative fluoro-
genic PCR,” etc. We use the acronym, “qPCR,” solely to 
connote this technique.
One-step qPcr refers to any approach to qPCR 
wherein the original nucleic acid isolate is used directly 
in a qPCR Master Mix without transformation. This can 
apply to both RNA and DNA. If your original isolate is 
RNA, or if your original isolate is DNA, and you use them 
directly in a qPCR Master Mix (presumably after DNase- 
or RNase-treating and/or pre-diluting them), you are per-
forming “One-Step qPCR.” It is important to keep the DN-
ase or RNase treatments here identical for every sample. 
Whether one is DNase-treating RNA or RNase-treating 
DNA, think of them both as the “same” procedure regard-
ing “template treatment.” Select the appropriate extinction 
coefficient for the nucleic acid type you are working with in 
“UMES.xls file” cell range R150:R153. (ε) Extinction coef-
ficient/1000 values are used, where ε = # μg/mL/1 o.d. @ 
260nm. The initial template type you are entering o.d. 260nm 
readings for will use an extinction coefficient of: 0.033 for 
oligo DNA, 0.037 for ssDNA, 0.04 for ssRNA and 0.05 for 
dsDNA. P-Q keeps track of every dilution all samples (for 
up to 72 samples in a One-Step qPCR approach when not 
using the “01AuxSmplFile.xls” file for additional sample 
entries) incur - from their isolation to their use in qPCR, 
and is, therefore, always aware of each sample’s ng/μL 
(DNA or RNA) concentration at every step along the way.
two-step qPcr refers to preparing cDNA from (usu-
ally DNase-treated) RNA first, and then using the pre-
prepared cDNA in a qPCR Master Mix. E.g. whenever an 
investigator intervenes to transform any isolated nucleic 
acid sample into a complementary nucleic acid in a separate 
step preceding qPCR, one is performing “Two-Step qPCR.” 
For such approaches, the user should strive to keep all such 
nucleic acid ‘transformations’ as identical as possible for all 
samples (i.e. use the same ng RNA per unit volume reverse 
transcription [cDNA synthesis] reaction for each sample, 
etc.); choose one approach for each such manipulation and 
stick with it for all samples. Use high-efficiency transforma-
computer Macro security Note: Due to the “Low” Macro security setting suggested to open, use and run the Excel/Visual Basic P-Q Macros smoothly 
and easily, users are advised to return the security setting back to what it was originally if cyber-security is an issue for you when your computer is ac-
tively connected to the internet. The other option is to only use the P-Q program when you are not connected to the internet. To date, no security problems 
have been encountered with the use of P-Q − even after leaving the Security setting at “Low” permanently. So, this statement is meant only to help people 
preemptively err on the safe side of this issue in the event that it ever becomes an issue in the first place. Additionally, remember to use only the Windows 
Office 2003 version of Excel to run the program – either on a PC or a Mac.
qPcr assay develoPment and Project management software
www.ijbs.org    Int  J  Biomed  Sci    vol. 4  no. 4    December  2008 291
tions. P-Q keeps track of any and all dilutions all samples 
(up to 60 samples in a Two-Step qPCR approach when not 
using the “01AuxSmplFile.xls” file for additional sample 
entries) incur throughout - from their isolation to their use 
in qPCR, and is, therefore, always aware of each sample’s 
ng/μL (cDNA) concentration at every step along the way.
P-Q’s default approach in calculating DNase treat-
ments of RNA preceding its use in reverse transcription 
(RT) reactions (preceding Two-Step qPCR) breaks away 
from the constraints mentioned in the above paragraph by 
allowing one to use different amounts of RNA per unit 
volume DNase-treatment reaction. This approach allows 
one to eliminate the addition of water to the DNase re-
actions (to save on DNase reaction set-up time). One can 
choose one’s own approach (via the “Questionnaire.xls” 
file) or use the P-Q default approach for this - both are OK.
It is important to mention the “Questionnaire.xls” file at 
this point since all new users of this program should fill it 
out right away. Custom use of P-Q draws on the values and 
responses placed into this file, so we urge users to fill it out 
immediately upon opening P-Q. Further, there are similar 
regions within the “UMES.xls” file that must be answered 
identically to the responses placed into the “Questionnaire.
xls” file. This is described in more detail on page 21 in the 
section entitled ‘The “Questionnaire.xls” file’ in the cur-
rent user manual (“PREXCEL-Q Manual 8-1-8”).
APPENDIX 2
the ~7 PrEXcEL-Q User Modes
After a full reset (Ctrl Shift K) of the system, you have 
7 directions to go:
a) Questionnaire.xls file-interfaced One-Step qPCR 
Mode. This mode relies upon the values and responses in-
vestigators enter into the “Questionnaire.xls” file pertaining 
to One-Step qPCR and is active when an “x” is entered into 
cell J7 of the “Questionnaire.xls” file, and a “y” is entered 
into cell I141 of the “UMES.xls” file. The Ctrl Shift F Macro 
introduces user values and characters into the system. Up-
dating changes and corrections to set-ups is accomplished 
by running the Ctrl Shift Z Macro. (For all modes, anytime 
one changes the number of samples or sample o.d. 260nm 
information, an initial global Macro must be run again to 
introduce the new sample parameters into the program. 
Here, that global Macro would be Ctrl Shift F). The more 
one enters parameters correctly from the start, the less one 
will have to re-run various Macros to get things right. 
b) Questionnaire.xls file-interfaced Two-Step 
qPcr Mode. This mode relies upon the values and re-
sponses investigators enter into the “Questionnaire.xls” 
file pertaining to Two-Step qPCR and is active when an 
“x” is entered in cell K7 of the “Questionnaire.xls” file 
and all required identical entries have been made in both 
the “Questionnaire.xls” and “UMES.xls” files - includ-
ing the entry of RNA o.d.260nm values into region B120:
B191 of the “UMES.xls” file after which the Macro Ctrl 
x is run. The system automatically enters a “y” entry 
into cell I141 of the “UMES.xls” file as part of the Ctrl 
x Macro’s response to the “x” above in K7. Updating 
changes and corrections to set-ups is accomplished by 
running the Ctrl Shift Z Macro, but, if changes are made 
which affect DNase- or RNase-treatment parameters or 
RT reaction parameters, the Macro Ctrl Shift N should 
be used instead of Ctrl Shift Z. “zPrinouts.xls” file tab 
(Excel worksheet) “QuesPQ” provides your sample dilu-
tions preceding DNase (or RNase) and RT reactions, and 
shows the user the DNase (or RNase) and RT reaction 
set-ups themselves. The “zPrinouts.xls” “QuesPQ” tab is 
provided solely for this mode.
c) P-Q default One-step qPcr Mode. This mode 
does not rely upon the values and responses investigators 
enter into the “Questionnaire.xls” file. It only responds to 
the values and entries made within the “UMES.xls” file, 
and is active when an “n” is entered into cell I141 of the 
“UMES.xls” file. The Ctrl Shift F Macro introduces user 
values and characters into the system. Updating changes 
and corrections to set-ups is accomplished by running the 
Ctrl Shift Z Macro.
d) P-Q default two-step qPcr Mode. When no 
“x” is entered into cell K7 of the “Questionnaire.xls” 
file, this mode is active and only responds to the values 
and entries made within the “UMES.xls” file, and is ac-
tive when an “n” is entered into cell I141 of the “UMES.
xls” file followed by running the Ctrl x Macro. Updat-
ing changes and corrections to set-ups is accomplished 
by running the Ctrl Shift Z Macro, but, if changes are 
made which affect DNase or RNase-treatment param-
eters, or RT reaction parameters, Ctrl Shift N should be 
used instead of Ctrl Shift Z for updating/informing the 
system of those particular changes. “zPrinouts.xls” file 
tabs “DNAse2Stp” and “RT2Stp” provide the DNase (or 
RNase) and RT reaction set-ups.
e) P-Q default LcM One-step qPcr Mode. This 
mode does not rely upon the values and responses inves-
tigators enter into the “Questionnaire.xls” file (and there-
fore does not even require one to type an “x” into cell J8 of 
the “Questionnaire.xls” file), it only responds to the values 
and entries made within the “UMES.xls” file and is active 
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when an “n” is entered into cell I141 of the “UMES.xls” 
file followed by running the Ctrl w Macro (~6 minutes). 
*Changes to LCM qPCR sample parameters in cell range 
L185:N197 of the “UMES.xls” file are introduced into the 
system using the Ctrl Shift T Macro, while updating any 
other subsequent changes or corrections to set-ups is ac-
complished by running Ctrl Shift Z. [*Ctrl w initiates P-Q 
into LCM-qPCR mode].
f) Quick Mode. This mode does not rely upon the 
values or responses investigators enter into the “Ques-
tionnaire.xls” file, and do not require sample A260nm 
entries either. It is designed to let users test as many 
primers, primer-probe sets or [beacon, scorpion, etc.] 
probes as quickly as possible without regard for sample 
status or preparation. It doesn’t even respond to most 
of the values and entries made within the “UMES.xls” 
file, and is active when an “n” is entered into cell I141 
of the “UMES.xls” file and only when non-zero entries 
are made within “UMES.xls” file cells I187 and I188. 
Values must also be entered into one or all of cells G190, 
G191 and G192 to tell the system the nM concentration 
of primers and/or probe to be used for all assessments. 
Only one choice for these concentrations is allowed here 
since it is the non-precise goal of this mode to allow us-
ers to merely quickly determine whether or not their 
primers and/or probe(s) work at all (SYBR Green users 
can employ this function to test many primer sets quick-
ly). The other requirement for this mode to function is 
that you must type how many replicates you will use per 
sample for these assessments in “UMES.xls” cell U25. 
It is also important that a “1” be typed into “UMES.xls” 
cell O25 as well. Updating changes to parameters is ac-
complished by running Ctrl y and Ctrl Shift Z Macros. 
But, remember, working in this mode stops the function-
ality of many other aspects of P-Q, and it is important to 
remember that the output (printout) for this use of P-Q 
is found only within the “SP MM” tab (spreadsheet) cell 
range A150:J177 within the “zPrintouts.xls” file. The 
“zPrintouts.xls” file contains 11 Excel worksheets which 
house the program’s printouts.
g) Exploratory (Free) Mode. This is the use of P-Q for 
other things besides qPCR - any dream you can dream - any 
other creative use of this program you can think of …
P-Q files you will directly use. During the routine use 
of this program, you will interact with only 5 (but possibly 
up to 7) of the 27 P-Q Excel files. These files are: 
• “Questionnaire.xls” - for user parameter entries.
• “UMES.xls” - for user parameter entries, 
• “TestPlateResultsAnalysis2006.xls” - for analyzing 
Test Plate Ct values to locate the LOG-linear-am-
plification-capable, high-efficiency-of-amplification 
ranges for each qPCR target. 
• “TestPlateResultsAnalysis2006b.xls” - also for ana-
lyzing Test Plate Ct values to locate the LOG-linear, 
high-efficiency amplification ranges for each target 
and to finally select the  valid dilution ranges for each 
of your qPCR target standard curves. 
• “zPrintouts.xls” - printouts for all reagent set-ups to 
use in the lab (11 Excel spreadsheets).
• “01AuxSmplFile.xls” for entering additional sample 
o.d.260nm readings. (This file is the most recent ad-
dition to the program; the 27th file, which allows for 
more than 60 sample entries for Two-Step and more 
than 72 sample entries for One-Step qPCR).
• “FinalLabPrintOutforDNaseandmakingcDNAs.xls” 
- for including the addition of water to DNase or 
RNase reactions when desired or needed. 
Note: The P-Q program relies on users already be-
ing familiar with some of the basic mechanics of using a 
Windows Excel spreadsheet. Users are required to know 
how to be sure your cursor is not still activated on a cell 
after you have entered a value or character there, and to 
know how to ‘Copy’ and ‘Paste Special Values.’ Simply 
clicking outside a cell after entering a value or character 
solves skill #1 above, and right-clicking the mouse or look-
ing through the Edit menu in the Excel toolbar guides one 
to the ‘Copy’ and ‘Paste Special Values’ commands. Us-
ing the ‘Copy’ command followed by the ‘Paste Special 
Values’ command allows one to preserve the original cell 
formatting in the program and prevents one from inad-
vertently or unintentionally pasting a formula instead of a 
value. I urge you to use the ‘Copy’ command followed by 
the ‘Paste Special Values’ operations in tandem whenever 
pasting anything into the program’s user-input regions - as 
opposed to using ‘Copy’ then the ‘Paste’ command. An-
other thing to note here is that users need not be alarmed 
by error messages such as #DIV/0!, #VALUE! or #N/A 
which appear throughout the program in various locations; 
these are all healthy manifestations of parts of the program 
that are either not being used (in cases which make the full 
use of P-Q unnecessary) or, the program is using the error 
messages to activate formulas in other cells that rely on 
exactly what kind of error messages they are.
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